Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Status
Status: Commission completed
Project no.
A21-90
Last updated

Report documents

  1. Extract of dossier assessment

    Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    published on
    Document type
    PDF document, 748 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 748 kB, EN, not accessible)

  2. Dossier assessment

    Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

Treatment of adults with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy

Result of dossier assessment:
  • Patients without prior stem cell therapy: Indication of major added benefit.
  • Patients with prior stem cell therapy: added benefit not proven.

Project details

Project no.
A21-90
Commission
Commission awarded on 01.07.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-80
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Elotuzumab - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-32
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page